Sedana Medical AB’s Interim report January-September 2023
All-time-high Q3 sales and further steps towards ex-US profitabilityThird quarter 2023 · Net sales for the quarter totalled MSEK 34.3 (26.5), equivalent to an increase of 29% compared to the same quarter 2022. At constant exchange rates, sales increased by 16%. · Gross profit was MSEK 23.9 (18.4) equivalent to a margin of 70% (70%). · Earnings before interest, taxes, depreciation and amortisation (EBITDA) totalled MSEK -12.6 (-25.1), equivalent to an EBITDA margin of -37% (-95%). EBITDA ex-US for the quarter was MSEK -11.5 (-22.8). · Operating income (EBIT) totalled MSEK -18.1